NorthWest Biotherapeutics Inc (NWBO)

[CherryTree1]

Here is at least some statements about mesenchmal subgroup likely being more response to immuno-therapy, a little dated but as you know some of the Liau video's have been removed from the internet.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278117/

Therapeutic Vaccine for Brain Cancer Succeeds Using a Unique Approach

Microarray gene-expression profiling revealed that Jones and the others in his trial who are still alive had tumors with mesenchymal gene-expression signatures. In the Prins study, an analysis of tumor tissue with a mesenchymal gene-expression signature showed that these tumors have a higher number of CD3+ and CD8+ tumor-infiltrating lymphocytes compared with glioblastomas with other gene-expression signatures. The authors theorized that “the mesenchymal gene-expression profile may identify an immunogenic subgroup of glioblastoma that may be more responsive to immune-based therapies.”

Cancer vaccines gain ground

The usual personalized medicine approach is to identify the molecular markers that predict a patient’s response to treatment. Liau and colleagues tried that. They analyzed GBMs for antigens and pulsed dendritic cells with the corresponding off-the-shelf synthetic peptides expressed by the tumors. Unfortunately, that trial did not improve patient survival.

“Why not just let the patient’s own body decide what to attack and get the antigens from the tumor itself?”

— Linda M. Liau, MD, PhD, David Geffen School of Medicine, UCLA

I haven't found the NIH % of subgroup chart yet, but here is one I found but has a smaller percentage of mesenchymal, only about 1/3rd here.
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0094871